EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP
Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies
Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.
Uncovering hidden genetic causes in adult cholestasis
Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.
Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency
Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
Targeted gene sequencing panel resolves unexplained cholestasis in about 5% of adults
A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.
Researchers call for ICP to be included in hepatobiliary risk stratification
Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.
Bilirubin and platelet count predict native liver survival in adolescents with ALGS
Researchers identify factors predicting improved native liver survival in adolescents with Alagille syndrome.
Genetic variants explain substantial proportion of undiagnosed cholestasis and hepatitis
Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.
AASLD 2025 Reflections: Key takeaways in primary sclerosing cholangitis
Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.
AASLD 2025 Reflections: Key takeaways in late-onset genetic cholestasis
Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.
AASLD 2025 Reflections: Key takeaways in primary biliary cholangitis
Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.
Seladelpar improves wellbeing and lowers itch impact
Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Survey reveals limitations to pruritus assessment in PSC
Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.
Ongoing seladelpar treatment continues to benefit PBC patients
Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.
Maralixibat offers clinically meaningful pruritus reductions in PSC
A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.
Genetic etiology may explain majority of adult-onset cholestatic disorders
Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.
Next generation sequencing may offer diagnoses in adult unexplained cholestasis
Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.
Gut microbiome may influence PSC development
Marios Nikolaidis shares findings on the gut microbiome in PSC management.
Digital mind–body intervention helps symptom management in liver disease
A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.
Volixibat improves fatigue and sleep in PBC alongside pruritus
An analysis of trial data indicates that, alongside reducing pruritus, volixibat helps normalize fatigue and sleep in PBC patients.
Novel panel identifies variants in unexplained cholestatic cases
A large US gene panel has helped to elucidate the underlying genetic basis of unexplained cholestasis.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
Sustained responses to elafibranor in PSC
Mitchell Shiffman comments on ELMWOOD findings for elafibranor in PSC.
PRO-C3 may illuminate liver disease progression in PBC
A correlation between PRO-C3 and liver measures in PBC suggests it could represent a novel disease biomarker.
Long-term elafibranor therapy improves PBC outcomes
ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.
Distressing PSC symptoms fit profiles that could guide treatment
US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.
Predictive model with standard clinical parameters differentiates PSC and SSC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
ELATIVE: Sustained elafibranor benefit and biomarker potential
Mark Swain on 3-year elafibranor benefits, proteomics in PBC.
Seladelpar cholestasis benefits extend long term
Discussing the ASSURE findings for seladelpar in PBC with Daniel Pratt.
Pharmacodynamic findings support linerixibat pruritus benefits in patients with PBC
Andreas Kremer explains post-hoc analysis findings from the phase 3 GLISTEN trial showing an effect of linerixibat on biomarkers and mediators of pruritus in patients with PBC.
NLP medical review may help identify adults with undiagnosed PFIC
Natural language programming could help identify which adults with cholestasis have late-onset progressive familial intrahepatic cholestasis.
Real-world data support seladelpar use in PBC patients switching from obeticholic acid
Real-world evidence supports seladelpar use in patients with PBC initiating seladelpar second-line or switching from obeticholic acid.
IBAT inhibitors may improve post-liver transplant pruritus
Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.
Responses to elafibranor in primary sclerosing cholangitis maintained after initial treatment
An open-label trial extension showed that the PPAR agonist elafibranor maintained efficacy, and former placebo patients saw improvements.
Contraceptives linked to unique cholestatic phenotype
Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.
Elafibranor improves symptom burden, unaffected by BMI
Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Deepak Joshi and Silvia Vilarinho
Dr Deepak Joshi and Dr Silvia Vilarinho discuss what’s ahead at AASLD 2025, focusing on late-onset genetic cholestasis and Alagille syndrome, and share what they are most looking forward to at this year’s meeting.
Countdown to AASLD 2025: A preview with Marlyn Mayo and Andreas Kremer
Dr Marlyn Mayo and Dr Andreas Kremer discuss what’s ahead at AASLD 2025, with a focus on advances in primary biliary cholangitis and primary sclerosing cholangitis. They share their perspectives on emerging research, key topics to watch, and what they are most looking forward to at this year’s meeting.
Updates on IBAT inhibitors from EASL 2025
Dr Richard Thompson and Dr Verena Keitel-Anselmino discuss the latest updates on IBAT inhibitors from EASL 2025, including their potential use in PBC patients based on promising phase I and II trial results.
Hepatocyte organoids offer PFIC modelling of bile duct damage
Preclinical findings at EASL Congress 2025 point to organoid models for different types of PFIC.
EASL guidelines offer ‘framework’ for intrahepatic cholestasis of pregnancy care
Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.
Pathogenic variants common in adult-onset cholestasis patients
Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.
Preclinical highlights of the EASL Congress 2025
Drs Richard Thompson and Verena Keitel-Anselmino discuss their cholestasis preclinical highlights from the EASL Congress 2025.
Intrahepatic cholestasis of pregnancy EASL guidelines aid risk stratification
Ms Nina Rodriguez and Dr Tatyana Kushner confirm that the 2023 EASL guidelines can help risk stratify patients with intrahepatic cholestasis of pregnancy.
ABCB4 variant genotype–phenotype relationship in cholestasis elucidated
Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.
Odevixibat update for adult PFIC, older Alagille syndrome patients
Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.
Unmet needs in late-onset genetic cholestasis: an expert discussion
This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).
IBAT trial updates confirm efficacy and safety for PFIC patients
Further findings on the efficacy and safety of ileal bile acid transporter inhibitors for patients with progressive familial intrahepatic cholestasis have been presented at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
Whole-exome sequencing aids adult-onset cholestatic liver disease diagnosis
Dr Miki Scaravaglio talks through her proof-of-principle study findings for use of whole-exome sequencing to aid the diagnosis of people with adult-onset cholestatic liver disease.
Whole-exome sequencing sheds light on unexplained adult-onset cholestatic liver disease
Whole-exome sequencing led to definitive diagnoses for almost a quarter of patients with unexplained adult-onset cholestatic liver disease, say Italian researchers.
ABCB11 alteration linked to anabolic steroid-induced liver injury susceptibility
Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.
PFIC trial updates continue to support IBAT inhibitor efficacy and safety
Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.
ABCB11 variants increase susceptibility to anabolic steroid-induced liver injury
Alterations to ABCB11 play a “pivotal role” in the development of drug-induced liver injury from anabolic steroids, US researchers reported at the 2024 AASLD The Liver Meeting in San Diego, California, USA.
Oral contraceptive absorption unhindered by odevixibat in healthy women
Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.
EASL guidelines direct genetic cholestatic liver management
An EASL expert panel has developed clinical practice guidelines for the management of progressive familial intrahepatic cholestasis and other genetic cholestatic liver diseases.
Combination therapies and real world treatment for PBC patients
Dr Adriaan Van der Meer shares his insights on the results from the combination trial of obeticholic acid and bezafibrate for PBC patients, presented at EASL 2024 in Milan, Italy. In addition, discover key findings and learn about the RECAPITULATE trial, focusing on real-world treatment outcomes.
Breaking analysis of ASSURE from EASL 2024
Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
